Evoke Pharma
Stock Forecast, Prediction & Price Target
Evoke Pharma Financial Estimates
Evoke Pharma Revenue Estimates
Evoke Pharma EBITDA Estimates
Evoke Pharma Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | ||
Revenue
% change YoY
| $1.61M N/A | $2.50M 55.03% | $5.18M 106.51% | Avg: $21.90M Low: $21.90M High: $21.90M avg. 322.80% | Avg: $32.02M Low: $32.02M High: $32.02M avg. 46.22% | ||
Net Income
% change YoY
| $-9.02M N/A | $-8.16M 9.60% | $-7.79M 4.53% | Avg: $3.23M Low: $334.30K High: $334.30K avg. 141.48% | Avg: $9.23M Low: $936.05K High: $936.05K avg. 185.55% | ||
EBITDA
% change YoY
| $-8.14M N/A | $-7.72M 5.14% | $-7.29M 5.59% | Avg: $-13.14M Low: $-13.14M High: $-13.14M avg. -80.22% | Avg: $-19.21M Low: $-19.21M High: $-19.21M avg. -46.22% | ||
EPS
% change YoY
| -$3.37 N/A | -$2.6 22.84% | -$27.97 -975.76% | Avg: $0.1 Low: $0.1 High: $0.1 avg. 100.35% | Avg: $0.28 Low: $0.28 High: $0.28 avg. 180% | ||
Operating Expenses
% change YoY
| $9.44M N/A | $9.92M 5.11% | $12.40M 25.04% | Avg: $1.27B Low: $1.27B High: $1.27B avg. 10205.88% | Avg: $1.87B Low: $1.87B High: $1.87B avg. 46.22% | ||
FAQ
What is Evoke Pharma stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 163.52% in 2025-2026.
We have gathered data from 1 analysts. Their low estimate is 334.30K, average is 3.23M and high is 334.30K.
What is Evoke Pharma stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 184.51% in 2025-2026.
We have gathered data from 1 analysts. Their low revenue estimate is $21.90M, average is $21.90M and high is $21.90M.
What is Evoke Pharma stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 140.17% in 2025-2026.
We have gathered data from 1 analysts. Their low earnings per share estimate is $0.1, average is $0.1 and high is $0.1.
What is the best performing analyst?
In the last twelve months analysts have been covering Evoke Pharma stock. The most successful analyst is Yale Jen.